RE:RE:RE:RE:RE:RE:Biotech buyouts.I suggest you re-read the panel displayed on page 38 and pay partiular attention to the panel subject matter headline. What you see is in this panely is the objective of a business development strategy anchored by partnerships with large pharmaceutical companies. This panel describes the objective in a joint development and commercialization partnership. Not a Big Pharma buyout !
The reason why ONCY would seek to maintain rights to North America in part or in whole in a joint commercilization arrangement would be to preclude any possibility of any putative Big Pharma licensing partner from "shelving" or minimizing it's commercialization activities for strategic reasons that go against ONCY's interests.
If you read what I have been posting you can deduce that Big Pharma is not interested in establishing a joint development and commercialization strategy particularly when Big Pharma is facing a looming patent cliff by 2024 and is seeking to fill its pipeline and have full control over the commercialization of its product line.